These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 17531925)

  • 1. Matrix metalloprotease activity is enhanced in the compensated but not in the decompensated phase of pressure overload hypertrophy.
    Tozzi R; Palladini G; Fallarini S; Nano R; Gatti C; Presotto C; Schiavone A; Micheletti R; Ferrari P; Fogari R; Perlini S
    Am J Hypertens; 2007 Jun; 20(6):663-9. PubMed ID: 17531925
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Matrix metalloproteinases and their tissue inhibitors in pressure-overloaded human myocardium during heart failure progression.
    Polyakova V; Hein S; Kostin S; Ziegelhoeffer T; Schaper J
    J Am Coll Cardiol; 2004 Oct; 44(8):1609-18. PubMed ID: 15489093
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease.
    Ahmed SH; Clark LL; Pennington WR; Webb CS; Bonnema DD; Leonardi AH; McClure CD; Spinale FG; Zile MR
    Circulation; 2006 May; 113(17):2089-96. PubMed ID: 16636176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concentric left ventricular remodeling in endothelial nitric oxide synthase knockout mice by chronic pressure overload.
    Ruetten H; Dimmeler S; Gehring D; Ihling C; Zeiher AM
    Cardiovasc Res; 2005 Jun; 66(3):444-53. PubMed ID: 15914109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extracellular matrix remodeling attenuated after experimental postinfarct left ventricular aneurysm repair.
    Hsu CP; Huang CY; Wang JS; Sun PC; Shih CC
    Ann Thorac Surg; 2008 Oct; 86(4):1243-9. PubMed ID: 18805169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor necrosis factor-alpha mediates cardiac remodeling and ventricular dysfunction after pressure overload state.
    Sun M; Chen M; Dawood F; Zurawska U; Li JY; Parker T; Kassiri Z; Kirshenbaum LA; Arnold M; Khokha R; Liu PP
    Circulation; 2007 Mar; 115(11):1398-407. PubMed ID: 17353445
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased cardiac expression of tissue inhibitor of metalloproteinase-1 and tissue inhibitor of metalloproteinase-2 is related to cardiac fibrosis and dysfunction in the chronic pressure-overloaded human heart.
    Heymans S; Schroen B; Vermeersch P; Milting H; Gao F; Kassner A; Gillijns H; Herijgers P; Flameng W; Carmeliet P; Van de Werf F; Pinto YM; Janssens S
    Circulation; 2005 Aug; 112(8):1136-44. PubMed ID: 16103240
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic pressure overload cardiac hypertrophy and failure in guinea pigs: I. Regional hemodynamics and myocyte remodeling.
    Wang X; Li F; Gerdes AM
    J Mol Cell Cardiol; 1999 Feb; 31(2):307-17. PubMed ID: 10093044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lack of tissue inhibitor of metalloproteinases 2 leads to exacerbated left ventricular dysfunction and adverse extracellular matrix remodeling in response to biomechanical stress.
    Kandalam V; Basu R; Moore L; Fan D; Wang X; Jaworski DM; Oudit GY; Kassiri Z
    Circulation; 2011 Nov; 124(19):2094-105. PubMed ID: 21986284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of apoptotic caspase cascade during the transition to pressure overload-induced heart failure.
    Moorjani N; Ahmad M; Catarino P; Brittin R; Trabzuni D; Al-Mohanna F; Narula N; Narula J; Westaby S
    J Am Coll Cardiol; 2006 Oct; 48(7):1451-8. PubMed ID: 17010810
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adenosine A1 receptor expression during the transition from compensated pressure overload hypertrophy to heart failure.
    Perlini S; Arosio B; Parmeggiani L; Santambrogio D; Palladini G; Tozzi R; Gatti C; Annoni G; Meyer TE; Ferrari AU
    J Hypertens; 2007 Feb; 25(2):449-54. PubMed ID: 17211253
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pravastatin increases survival and suppresses an increase in myocardial matrix metalloproteinase activity in a rat model of heart failure.
    Ichihara S; Noda A; Nagata K; Obata K; Xu J; Ichihara G; Oikawa S; Kawanishi S; Yamada Y; Yokota M
    Cardiovasc Res; 2006 Feb; 69(3):726-35. PubMed ID: 16165109
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Excessive activation of matrix metalloproteinases coincides with left ventricular remodeling during transition from hypertrophy to heart failure in hypertensive rats.
    Iwanaga Y; Aoyama T; Kihara Y; Onozawa Y; Yoneda T; Sasayama S
    J Am Coll Cardiol; 2002 Apr; 39(8):1384-91. PubMed ID: 11955860
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The plasminogen-MMP system is more activated in the scar than in viable myocardium 3 months post-MI in the rat.
    Gaertner R; Jacob MP; Prunier F; Angles-Cano E; Mercadier JJ; Michel JB
    J Mol Cell Cardiol; 2005 Jan; 38(1):193-204. PubMed ID: 15623436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of left ventricular volume overload on mitochondrial and death-receptor-mediated apoptotic pathways in the transition to heart failure.
    Moorjani N; Westaby S; Narula J; Catarino PA; Brittin R; Kemp TJ; Narula N; Sugden PH
    Am J Cardiol; 2009 May; 103(9):1261-8. PubMed ID: 19406269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential regulation of extracellular matrix constituents in myocardial remodeling with and without heart failure following pressure overload.
    Skrbic B; Bjørnstad JL; Marstein HS; Carlson CR; Sjaastad I; Nygård S; Bjørnstad S; Christensen G; Tønnessen T
    Matrix Biol; 2013 Mar; 32(2):133-42. PubMed ID: 23220517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective induction of matrix metalloproteinases and tissue inhibitor of metalloproteinases in atrial and ventricular myocardium in patients with atrial fibrillation.
    Mukherjee R; Herron AR; Lowry AS; Stroud RE; Stroud MR; Wharton JM; Ikonomidis JS; Crumbley AJ; Spinale FG; Gold MR
    Am J Cardiol; 2006 Feb; 97(4):532-7. PubMed ID: 16461051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Calcineurin and matrix protein expression in cardiac hypertrophy: evidence for calcineurin B to control excessive hypertrophic signaling.
    Grammer JB; Bleiziffer S; Monticelli F; Lange R; Bauernschmitt R
    Basic Res Cardiol; 2006 Jul; 101(4):292-300. PubMed ID: 16688406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. K(ATP) activation prevents progression of cardiac hypertrophy to failure induced by pressure overload via protecting endothelial function.
    Gao S; Long CL; Wang RH; Wang H
    Cardiovasc Res; 2009 Aug; 83(3):444-56. PubMed ID: 19304734
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Involvement of the nicotinamide adenosine dinucleotide phosphate oxidase isoform Nox2 in cardiac contractile dysfunction occurring in response to pressure overload.
    Grieve DJ; Byrne JA; Siva A; Layland J; Johar S; Cave AC; Shah AM
    J Am Coll Cardiol; 2006 Feb; 47(4):817-26. PubMed ID: 16487851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.